Cyclo Non Currrent Assets Other vs Common Stock Shares Outstanding Analysis

CYTHW Stock  USD 0.14  0.00  0.00%   
Cyclo Therapeutics financial indicator trend analysis is way more than just evaluating Cyclo Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cyclo Therapeutics is a good investment. Please check the relationship between Cyclo Therapeutics Non Currrent Assets Other and its Common Stock Shares Outstanding accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
For more information on how to buy Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

Non Currrent Assets Other vs Common Stock Shares Outstanding

Non Currrent Assets Other vs Common Stock Shares Outstanding Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cyclo Therapeutics Non Currrent Assets Other account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Cyclo Therapeutics' Non Currrent Assets Other and Common Stock Shares Outstanding is -0.4. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Cyclo Therapeutics, assuming nothing else is changed. The correlation between historical values of Cyclo Therapeutics' Non Currrent Assets Other and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Cyclo Therapeutics are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Non Currrent Assets Other i.e., Cyclo Therapeutics' Non Currrent Assets Other and Common Stock Shares Outstanding go up and down completely randomly.

Correlation Coefficient

-0.4
Relationship DirectionNegative 
Relationship StrengthVery Weak

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.
Most indicators from Cyclo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cyclo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
For more information on how to buy Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.At this time, Cyclo Therapeutics' Issuance Of Capital Stock is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to climb to 5.52 in 2024, whereas Enterprise Value Over EBITDA is likely to drop (0.93) in 2024.
 2021 2022 2023 2024 (projected)
Total Operating Expenses15.7M16.8M17.6M18.5M
Cost Of Revenue156.1K138.9K3.5M3.7M

Cyclo Therapeutics fundamental ratios Correlations

0.150.740.85-0.22-0.96-0.710.810.98-0.28-0.350.980.680.64-0.23-0.160.530.790.730.990.4-0.28-0.42-0.51-0.180.38
0.150.41-0.150.610.11-0.390.14-0.030.570.31-0.03-0.320.580.41-0.140.450.370.470.040.76-0.21-0.37-0.490.65-0.71
0.740.410.29-0.27-0.64-0.950.940.68-0.34-0.480.680.250.94-0.07-0.20.740.950.990.750.79-0.23-0.18-0.37-0.230.22
0.85-0.150.29-0.15-0.89-0.30.450.88-0.19-0.190.880.790.18-0.26-0.040.20.40.280.84-0.04-0.23-0.43-0.41-0.120.43
-0.220.61-0.27-0.150.420.39-0.49-0.350.990.73-0.35-0.35-0.170.030.12-0.35-0.38-0.22-0.360.05-0.12-0.09-0.081.0-0.82
-0.960.11-0.64-0.890.420.63-0.79-0.990.470.46-0.99-0.74-0.50.280.16-0.45-0.71-0.62-0.98-0.220.20.370.420.39-0.58
-0.71-0.39-0.95-0.30.390.63-0.91-0.660.460.56-0.66-0.3-0.95-0.170.23-0.9-0.99-0.94-0.74-0.820.240.290.450.34-0.27
0.810.140.940.45-0.49-0.79-0.910.8-0.55-0.60.80.440.81-0.13-0.260.70.930.930.850.58-0.24-0.13-0.28-0.450.48
0.98-0.030.680.88-0.35-0.99-0.660.8-0.4-0.421.00.710.55-0.29-0.170.460.740.670.990.28-0.22-0.39-0.46-0.320.51
-0.280.57-0.34-0.190.990.470.46-0.55-0.40.8-0.4-0.36-0.240.030.12-0.41-0.45-0.28-0.42-0.03-0.15-0.04-0.020.98-0.8
-0.350.31-0.48-0.190.730.460.56-0.6-0.420.8-0.42-0.25-0.4-0.010.02-0.49-0.55-0.42-0.46-0.28-0.190.030.080.71-0.53
0.98-0.030.680.88-0.35-0.99-0.660.81.0-0.4-0.420.710.55-0.29-0.170.460.740.670.990.28-0.22-0.39-0.46-0.320.51
0.68-0.320.250.79-0.35-0.74-0.30.440.71-0.36-0.250.710.18-0.25-0.070.220.370.230.7-0.14-0.25-0.07-0.06-0.320.58
0.640.580.940.18-0.17-0.5-0.950.810.55-0.24-0.40.550.180.1-0.210.810.940.950.640.9-0.18-0.3-0.49-0.130.03
-0.230.41-0.07-0.260.030.28-0.17-0.13-0.290.03-0.01-0.29-0.250.1-0.190.560.11-0.06-0.220.34-0.06-0.35-0.290.05-0.31
-0.16-0.14-0.2-0.040.120.160.23-0.26-0.170.120.02-0.17-0.07-0.21-0.19-0.26-0.22-0.27-0.17-0.02-0.430.490.490.120.1
0.530.450.740.2-0.35-0.45-0.90.70.46-0.41-0.490.460.220.810.56-0.260.870.730.560.8-0.18-0.41-0.5-0.30.11
0.790.370.950.4-0.38-0.71-0.990.930.74-0.45-0.550.740.370.940.11-0.220.870.940.810.79-0.25-0.33-0.48-0.330.29
0.730.470.990.28-0.22-0.62-0.940.930.67-0.28-0.420.670.230.95-0.06-0.270.730.940.730.79-0.23-0.21-0.4-0.170.16
0.990.040.750.84-0.36-0.98-0.740.850.99-0.42-0.460.990.70.64-0.22-0.170.560.810.730.38-0.24-0.39-0.48-0.330.49
0.40.760.79-0.040.05-0.22-0.820.580.28-0.03-0.280.28-0.140.90.34-0.020.80.790.790.38-0.18-0.29-0.460.09-0.26
-0.28-0.21-0.23-0.23-0.120.20.24-0.24-0.22-0.15-0.19-0.22-0.25-0.18-0.06-0.43-0.18-0.25-0.23-0.24-0.18-0.33-0.28-0.15-0.28
-0.42-0.37-0.18-0.43-0.090.370.29-0.13-0.39-0.040.03-0.39-0.07-0.3-0.350.49-0.41-0.33-0.21-0.39-0.29-0.330.97-0.10.27
-0.51-0.49-0.37-0.41-0.080.420.45-0.28-0.46-0.020.08-0.46-0.06-0.49-0.290.49-0.5-0.48-0.4-0.48-0.46-0.280.97-0.10.27
-0.180.65-0.23-0.121.00.390.34-0.45-0.320.980.71-0.32-0.32-0.130.050.12-0.3-0.33-0.17-0.330.09-0.15-0.1-0.1-0.81
0.38-0.710.220.43-0.82-0.58-0.270.480.51-0.8-0.530.510.580.03-0.310.10.110.290.160.49-0.26-0.280.270.27-0.81
Click cells to compare fundamentals

Cyclo Therapeutics Account Relationship Matchups

Cyclo Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets4.1M14.2M19.5M4.2M13.2M13.9M
Total Current Liabilities3.1M3.7M3.8M3.5M8.5M8.9M
Total Stockholder Equity936.0K10.5M15.7M734.5K4.8M2.6M
Property Plant And Equipment Net64.6K87.9K77.2K56.7K929.3K505.7K
Net Debt(2.7M)(12.7M)(16.4M)(1.5M)(8.2M)(7.8M)
Retained Earnings(25.1M)(34.1M)(48.3M)(63.8M)(83.9M)(79.7M)
Accounts Payable3.1M3.5M3.7M2.2M4.9M5.1M
Cash2.8M12.8M16.6M1.5M9.2M9.7M
Non Current Assets Total155.2K137.7K84.5K56.7K929.3K694.6K
Non Currrent Assets Other90.6K49.8K7.3K(56.7K)38.3K36.4K
Cash And Short Term Investments2.8M12.8M16.6M1.5M9.2M9.7M
Net Receivables182.5K111.8K539.1K55.0K122.4K105.2K
Common Stock Shares Outstanding1.1M1.6M6.4M8.4M16.3M17.1M
Liabilities And Stockholders Equity4.1M14.2M19.5M4.2M13.2M13.9M
Non Current Liabilities Total36.1K62.9K18.0K3.5M22.5K21.4K
Inventory242.6K237.9K227.4K254.5K254.4K250.7K
Other Current Assets749.2K854.4K2.1M4.6M2.7M2.8M
Other Stockholder Equity26.0M44.5M64.0M64.5M88.6M93.0M
Total Liab3.2M3.7M3.8M3.5M8.5M8.9M
Total Current Assets4.0M14.1M19.4M4.2M12.3M12.9M
Common Stock12.2K477.0841.0849.02.9K3.7K
Common Stock Total Equity9.1K12.2K477.0849.0976.35927.53
Property Plant And Equipment Gross64.6K87.9K159.3K158.2K1.1M533.5K
Capital Surpluse18.7M26.0M44.5M64.5M74.2M77.9M
Property Plant Equipment18.6K64.6K87.9K55.2K63.5K51.7K
Net Invested Capital936.0K10.6M15.8M734.5K4.8M5.5M
Net Working Capital816.9K10.4M15.6M677.9K3.9M5.2M
Capital Stock12.2K477.0841.0849.02.9K3.5K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cyclo Stock Analysis

When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.